期刊
THERAPEUTIC ADVANCES IN UROLOGY
卷 6, 期 2, 页码 74-77出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1756287213513488
关键词
prostate health index; phi; prostate cancer; PSA; free PSA; screening; prognosis
资金
- Louis Feil Charitable Lead Trust
- National Institutes of Health [K07CA178258]
A major focus in urologic research is the identification of new biomarkers with improved specificity for clinically-significant prostate cancer. A promising new test based on prostate-specific antigen (PSA) is called the Prostate Health Index (PHI), which has recently been approved in the United States, Europe and Australia. PHI is a mathematical formula that combines total PSA, free PSA and [-2] proPSA. Numerous international studies have consistently shown that PHI outperforms its individual components for the prediction of overall and high-grade prostate cancer on biopsy. PHI also predicts the likelihood of progression during active surveillance, providing another noninvasive modality to potentially select and monitor this patient population. This article reviews the evidence on this new blood test with significant promise for both prostate cancer screening and treatment decisionmaking.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据